Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
MWN-AI** Summary
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) has officially launched the call for applications for the 9th Annual Route 79, The Duchenne Scholarship Program, aimed at supporting individuals impacted by Duchenne muscular dystrophy (Duchenne). This initiative provides academic scholarships of up to $5,000 each for up to 20 individuals diagnosed with Duchenne and five siblings of affected individuals for the 2026-2027 academic year. Applications will be accepted until May 15, 2026, at 11:59 p.m. PDT.
Diane Berry, Ph.D., Sarepta's Chief Global Policy & Advocacy Officer, emphasized the program's importance, stating that recent advancements in Duchenne treatment have created new opportunities for affected individuals. The Route 79 Scholarship Program not only honors these achievements but actively supports the educational aspirations of young adults within the Duchenne community. Each recipient brings unique insights from their personal experiences, enriching their academic journeys.
Recent scholars, such as Charles Cooley, have expressed gratitude for how the scholarship has enhanced their college experience, enabling them to pursue their education and make valuable connections. The program is open to applicants who are either enrolled in or accepted to an accredited college, university, or vocational school within the U.S. Notably, previous scholarship recipients can reapply, though they are limited to four awards throughout their educational journeys.
To learn more about the scholarship's criteria and application process, interested individuals can visit sarepta.com/route79. The Route 79 program, named after the 79 exons of the dystrophin gene, underscores Sarepta's commitment to guiding those affected by Duchenne toward achieving their academic and professional goals.
MWN-AI** Analysis
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) has taken another pivotal step in advancing the education and well-being of individuals affected by Duchenne muscular dystrophy (DMD) through its announcement of the Route 79 Duchenne Scholarship Program for the 2026-2027 academic year. The company plans to award scholarships of up to $5,000 to 20 eligible students and five siblings of individuals living with DMD, fostering educational aspirations within this unique community.
From a market perspective, this initiative underscores Sarepta's commitment not only to its therapeutic outcomes but also to community engagement and corporate responsibility. Investors should view this effort as enhancing brand loyalty and strengthening Sarepta's reputation within the rare disease community. The scholarship program demonstrates the company’s dedication to supporting patients and their families, resonating deeply in a market increasingly driven by corporate social responsibility.
Moreover, considering the advancements in DMD treatments, as highlighted by Sarepta’s leadership in precision genetic medicine, positive sentiment can be expected as advancements may bolster investor confidence. As new therapies become available, the perception of the company as a thought leader will be critical. This reputation can have a long-term impact on sales and market share as patients and healthcare providers increasingly rely on Sarepta's innovations.
Potential investors might find the following strategies beneficial: first, keep an eye on Sarepta's research and development updates, which could influence stock performance significantly. Second, monitor community engagement outcomes, as successful scholarship programs can yield positive PR and enhance investor sentiment. Lastly, consider how advancements in treatments for DMD might lead to increased patient enrollments in clinical endeavors. Investing in Sarepta could align with a broader strategy focused on socially responsible companies poised for growth in niche therapeutics.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
– Applications for the 2026-2027 academic year will be accepted until May 15, 2026
– Scholarships will be awarded to up to 20 individuals living with Duchenne muscular dystrophy and up to five siblings of individuals living with Duchenne
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the 2026-2027 academic year. Academic scholarships of up to $5,000 will be awarded to as many as 20 individuals living with Duchenne muscular dystrophy and five siblings of individuals living with Duchenne.
“Since this program began nine years ago, significant progress has been made in the treatment of Duchenne muscular dystrophy, opening up new possibilities for individuals living with Duchenne,” said Diane Berry, Ph.D., executive vice president and Chief Global Policy & Advocacy Officer at Sarepta. “The Route 79 Duchenne Scholarship Program honors these opportunities by supporting the educational ambitions of young adults in the Duchenne community. On behalf of Sarepta and the selection committee, we warmly encourage students living with Duchenne—or those who have a sibling with Duchenne—to apply as they pursue their academic dreams for the coming year. The first-hand experiences and unique perspectives of patients and families living with Duchenne bring valuable insights, resilience and determination to their educational journeys. We are excited to meet this year’s applicants and help Route 79 scholars embark on the next chapter of their academic journey.”
Charles Cooley, 2025 recipient of the Route 79 Scholarship, remarked, "Sarepta’s Route 79 Scholarship has enabled me to pursue my love of learning [and] I can’t tell you how much I have enjoyed college this year. I’ve met new friends, attended football games, basketball games and most importantly learned so much in my classes. My world has expanded greatly!"
Charles’ brother, James Cooley, 2025 recipient of the Route 79 sibling scholarship added, “The Route 79 Duchenne Scholarship Program has allowed me the ability to pursue an education at The University of Texas and I am forever grateful for the opportunities the program has provided me.”
To apply for a scholarship through the Route 79 program, applicants must be accepted to or enrolled in an accredited college or university, or a trade, technical or vocational school located in the United States. Only applicants diagnosed with Duchenne or applicants who have a sibling diagnosed with Duchenne are eligible for the program. College seniors or college graduates accepted to or enrolled in graduate school are also eligible to apply. Previous recipients of Route 79 scholarships may apply for the Scholarship Program; however, applicants may only receive a Route 79 scholarship up to four times. The selection of awardees is made by an independent committee, without consideration to and blinded as to whether an applicant was previously, is currently, or expects to be in the future, undergoing treatment with a Sarepta product or investigational therapy.
Applications will be accepted until Friday, May 15, 2026, at 11:59 p.m. PDT. Recipients will be notified prior to July 31, 2026, and awards will be distributed directly to the school, college or university in time for fall 2026 enrollment. Students may learn more about the program, application criteria, and how to apply by visiting Sarepta.com/route79 .
About Route 79, The Duchenne Scholarship Program
The Route 79 program is designed to help students living with Duchenne and siblings of individuals living with Duchenne pursue their post-secondary educational goals. Scholarship recipients are selected by an independent committee of Duchenne community members based on an applicant’s academic and community involvement, personal essay, and recommendation letter. The underlying cause of Duchenne is a difference in the gene coding for dystrophin. Dystrophin is an essential protein that plays a pivotal role in muscle structure, function and preservation. The numerical significance of the scholarship’s name, Route 79, ties to the 79 exons of the dystrophin gene. For more information, visit sarepta.com/route79 .
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com . We encourage investors and potential investors to consult our website regularly for important information about us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260227399135/en/
Investor:
Ian Estepan
617-274-4052
iestepan@sarepta.com
Ryan Wong
617-800-4112
rwong@sarepta.com
Media:
Kara Hoeger
617-710-3898
KHoeger@sarepta.com
FAQ**
How does Sarepta Therapeutics Inc. SRPT plan to measure the impact of the Route 79 Scholarship Program on the educational outcomes of recipients living with Duchenne muscular dystrophy?
Can you provide details on how previous recipients of the Route 79 Scholarship have utilized the funding from Sarepta Therapeutics Inc. SRPT to enhance their academic experiences?
What specific criteria does the independent selection committee use to evaluate applicants for the Route 79 Scholarship Program offered by Sarepta Therapeutics Inc. SRPT?
How does Sarepta Therapeutics Inc. SRPT plan to promote awareness of the Route 79 Scholarship Program to ensure eligible individuals living with Duchenne are informed about the opportunity?
**MWN-AI FAQ is based on asking OpenAI questions about Sarepta Therapeutics Inc. (NASDAQ: SRPT).
NASDAQ: SRPT
SRPT Trading
-4.03% G/L:
$17.165 Last:
1,202,704 Volume:
$17.54 Open:
